Preclinical Evaluation of the Efficacy of the Cyclin-Dependent Kinase Inhibitor Ribociclib in Combination with Letrozole against Patient-Derived Glioblastoma Cells

In a phase 0/I trial in patients with recurrent glioblastoma (GBM), investigators observed that letrozole permeates into the GBM tissue and triggers dose-dependent changes in the expression of genes regulating the cell cycle.